A Case of Kaposi's Sarcoma Improved by Sirolimus Treatment in the Kidney Transplant Recipient.
- Author:
Seung Min LEE
1
;
So Yeon PARK
;
Soo Jin KIM
;
Young Soo SONG
;
Heon Ho SONG
;
Samuel LEE
;
Eun Sook NAM
;
Jieun OH
Author Information
1. Department of Internal Medicine, Kidney Research Institute, Hallym University College of Medicine, Seoul, Korea. jieunmd@hallym.or.kr
- Publication Type:Case Report
- Keywords:
Kaposi's sarcoma;
Kidney transplantation;
Sirolimus
- MeSH:
Calcineurin;
Cyclosporine;
Humans;
Immunosuppressive Agents;
Incidence;
Kidney;
Kidney Transplantation;
Lymphatic Diseases;
Rejection (Psychology);
Sarcoma, Kaposi;
Sirolimus;
Skin;
Transplants
- From:Korean Journal of Nephrology
2009;28(1):82-87
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The incidence of Kaposi's sarcoma (KS) increases in kidney transplant recipients who had the immunosuppressive therapy. The usual treatment of KS is to reduce the dosage of immunosuppressive agents, with chemotherapy and/or radiotherapy. Several studies have recently demonstrated that the conversion to proliferation signal inhibitors (PSIs) from calcineurin inhibitors (CNI) leads to the remission of some post-transplant tumors such as KS. PSIs were well tolerated with stable renal function and no episode of acute rejection was reported. On the basis of these findings, we report a case of Kaposi's sarcoma in the kidney transplant patient, who had multiple lymphadenopathy and hepatic involvement without skin lesions. This patient responded well to the change of the immunosuppressive treatment from cyclosporine to sirolimus, one of PSIs.
